Download as PDF, PPTX
Uploaded byInfinIT - Innovationsnetværket for it
Johan seltborg presentation danmark 2018-06-21
This document discusses spasticity management and Inerventions' product called Mollii, which uses electrical therapy to reduce spasticity and improve motor control for people with conditions like cerebral palsy, stroke, and multiple sclerosis. Mollii is a medical device suit with electrodes that can be individually programmed. Clinical studies in Sweden and Denmark show that Mollii reduces spasticity and facilitates voluntary movement, helping users to live more freely. Inerventions' vision is for Mollii to become a natural first choice for non-invasive spasticity management.
Johan seltborg presentation danmark 2018-06-21
- 1. Taking spasticity managementand motor control into the future
- 2. Inerventions hjälper människormed funktionsvariation till ett bättre liv genom unika lösningar och hjälpmedel. Vi har idag produkten Mollii, som med elektroterapi dämpar rörelsehinder och smärta för personer med hjärn- och ryggmärgsskada, t ex stroke och CP. Vi vill bidra till ett samhälle där alla människor kan nå sin fulla potential. Ju fler som deltar fullt ut i samhället, desto bättre för demokrati, jämställdhet och mänskliga rättigheter. Vår vision är ett samhälle där alla har samma fysiska förutsättningar att leva fritt och självständigt. Inerventions
- 3. Swedish company Founded 2010 12employees Turnover ~10 MSEK Owned by founder, investors and employees
- 4. Spasticity Common consequenceof brain or spinal cord injury CP Stroke MS Etc. Muscle rigidity Involontary movements
- 5.
- 6. Spasticity Management Tomorrow Spasticity Management Botulinum toxin Baclofen PhysiotherapyRhizotomy Electrical Therapy
- 7. Electrical Therapy → SystematicReview of 14 independent studies – April 2016 → ”Level 1 and 2 evidence for TENS improving spasticity-related outcome measures”
- 8. The Application: Mollii Medical Device class II A Suit with 58 electrodes 24 sizes Control unit with individualisation Like integrated TENS Launched in 2013 ~1200 users today in 12 countries
- 9. The Mechanism: Reciprocal Inhibition ReciprocalInhibition Reciprocal inhibiton is not one type of reflex Stretch reflex Autogenic inhibition reflex Flexor reflex Recurrent inhibition→Renshaw Excitatory Interneurons Inhibitory interneurons Motor neurons
- 10. The Mission Reduce spasticity Facilitatevolontary movement Reduce pain MOLLII SHOULD BE THE NATURAL FIRST CHOICE - Non-invasive - Immediate effect - Cost effective - No side effects
- 11.
- 12. Recommended Use 1 hour 3-7times / week Indoor At home, in school, in training… Complement or alternative to other methods
- 13. Mollii in Sweden ~700 users 75% private purchase CP, stroke, MS most common Mollii as technical aid Habilitering/ technical aid centre Mollii as working aid Molii as treatment Molii as treatment Labour office Hospital: Spasticity Department Hospital: Primary care Official Health Care
- 14. Mollii in Denmark ~100Mollii users >20 kommuner approval (technical aid) Clinical study in Hvidovre (Christian Wong)
- 15. Christian Wong Consultant inPed. Orthopedics, PhD Hvidovre university hospital, Copenhagen, Denmark Mollii treatment in Cerebral Palsy.
- 16. Ongoing study withthe Mollii suit in 30 CP children, GFMCS 3-5. A clinical study The outcome measures are spasticity, stability, sleep, pain, bowel function and quality of life. 30 included, 1 finished, 2 paused due to epilepsy, 5 drop outs due to lack of effect and epilepsy, estimated study end spring (may) 2018.
- 17. Ongoing study withthe Mollii suit in 30 CP children, GFMCS 1-2. A clinical study The outcome measures are spasticity measured by the neuroflexor and gait analysis before and after. 30 included, estimated study end fall 2018.
- 18. Ongoing study withthe Mollii suit in 30 CP children, GFMCS 1-2. A mechanism study The outcome measure is the neural component of spasticity, measured by the instrument Neuroflexor®. 30 included, 15 tested with baseline, 20 Hz, 30 Hz and ‘suit only’, estimated study end spring 2018. .
- 19. Other Clinical Trials Theoretical framework: KI 2017 Linköping / borås 2014 15 adults with stroke 15 children with CP Luleå 2015 6 children with CP Falun CPUP 2016 17 children with CP Finished Q1 2017 Eurostars Multi-Centre Study (mechanism and clinical studies) KI (30 stroke) Hvidovre (60 CP) MU Vienna Paris St Maurice 4 children with CP
- 20.
- 21.
- 22.
- 23.
- 24.